News and Events
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION – Cambridge Healthtech Institute August 8-9, 2019
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION, PANEL DISCUSSION: Partnering and Licensing in Immuno-Oncology at the Cambridge Healthtech Institute’s 4th Annual Neoantigen Targeted Therapies Personalized Cancer...
2019 ASCO Annual Meeting
Abstract Title: Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors. Session Title/Date/Time: Poster Session: Developmental Immunotherapy and Tumor Immunobiology, 6/1/2019, 8:00 AM-11:00 AM May 31 – June 4, 2019...
Precision Biologics and NCI investigators to discuss NEO-201 development program at First Internation Congress of Bioimmunotherapy of Cancer
First international congress of BIOIMMUNOTHERAPY OF CANCER An International multidisciplinary meeting 12-13-14 APRILE 2019 REGGIO CALABRIA ITALY Palazzo della Provincia, Sala Perri, Piazza Italia, 89125 Reggio Calabria
An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.
Fantini M, David JM, Wong HC, Annunziata CM, Arlen PM, Tsang KY. Cancer Biother Radiopharm. 2019 Apr;34(3):147-159.
AACR Annual Meeting
Mechanisms of action of a neoantigen-targeting antibody NEO-201 AACR Annual Meeting - March 30-April 4 2019 - Atlanta, Georgia Session Category: Clinical Research Session Title: Immunomodulation by Chemotherapy and Targeted Agents Session Date and...
Dr. Philip M Arlen to deliver to presentations on the NEO-201 program at the Molecular Med Tri-Con Meetings, March 10-15th, SF, CA
The Discovery and Development of Novel Monoclonal Antibody, NEO-201 Targeting a Novel Neoantigen Philip M. Arlen, M.D.March, 2019
The National Cancer Institute Opens Clinical Trial Testing Safety and Dosing of NEO-201 Antibody in Patients with Advanced Cancer
Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer NIH 11/01/2018 Patients with advanced solid tumors may be eligible to participate in a new clinical trial at the NIH Clinical Center.
Precision Biologics along with Dr Christina Annunziata, MD, PhD, from the NCI are presenting at the AACR Annual Meeting
The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the inhibitory CEACAM5/CEACAM1 immune checkpoint pathway Session Category: Immunology Session Title: Therapeutic Antibodies, Including Engineered Antibodies...
Precision Biologics manuscript on our NEO-201 Antibody article published in Frontiers in Immunology
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
Dr. Philip Arlen to Speak at Immunotherapy Progress and Clinical Treatments
Dr. Philip Arlen to Speak at Immunotherapy Progress and Clinical Treatments December 5-7, 2017 in San Diego, CA